Report Detail

Other Global Peptide CDMO Services Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4556848
  • |
  • 17 September, 2023
  • |
  • Global
  • |
  • 121 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

According to our (Global Info Research) latest study, the global Peptide CDMO Services market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
Peptide CDMO services refer to peptide drug development and manufacturing outsourcing services. Polypeptides are short-chain proteins composed of amino acids and have a wide range of biological activities and pharmacological applications.
Peptide CDMO services usually cover the following aspects: peptide synthesis, process development, quality control, scale production, injection preparation. By choosing peptide CDMO services, the development and manufacture of peptide drugs can be handed over to professional institutions, thereby saving time, reducing costs, and ensuring product quality and compliance.
The Global Info Research report includes an overview of the development of the Peptide CDMO Services industry chain, the market status of Clinical Treatment (Small Molecule CDMO, Macro-molecular CDMO), Medical Research (Small Molecule CDMO, Macro-molecular CDMO), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Peptide CDMO Services.
Regionally, the report analyzes the Peptide CDMO Services markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Peptide CDMO Services market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Peptide CDMO Services market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Peptide CDMO Services industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Small Molecule CDMO, Macro-molecular CDMO).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Peptide CDMO Services market.
Regional Analysis: The report involves examining the Peptide CDMO Services market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Peptide CDMO Services market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Peptide CDMO Services:
Company Analysis: Report covers individual Peptide CDMO Services players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Peptide CDMO Services This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Clinical Treatment, Medical Research).
Technology Analysis: Report covers specific technologies relevant to Peptide CDMO Services. It assesses the current state, advancements, and potential future developments in Peptide CDMO Services areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Peptide CDMO Services market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Peptide CDMO Services market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Small Molecule CDMO
Macro-molecular CDMO
Market segment by Application
Clinical Treatment
Medical Research
Commercial Production
Market segment by players, this report covers
Incyte
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Zhejiang Jiuzhou Pharmaceutical
Sinopep
Frontier Biotechnologies
JYMed
Chengdu Shengnuo Biotechnology
Shanghai Soho-Yiming Pharmaceuticals
Chinese Peptide Company
Ambio Pharmaceuticals
Zhejiang Peptites Biotech
STA Pharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Peptide CDMO Services product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Peptide CDMO Services, with revenue, gross margin and global market share of Peptide CDMO Services from 2018 to 2023.
Chapter 3, the Peptide CDMO Services competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Peptide CDMO Services market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide CDMO Services.
Chapter 13, to describe Peptide CDMO Services research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Peptide CDMO Services
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Peptide CDMO Services by Type
    • 1.3.1 Overview: Global Peptide CDMO Services Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Peptide CDMO Services Consumption Value Market Share by Type in 2022
    • 1.3.3 Small Molecule CDMO
    • 1.3.4 Macro-molecular CDMO
  • 1.4 Global Peptide CDMO Services Market by Application
    • 1.4.1 Overview: Global Peptide CDMO Services Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Clinical Treatment
    • 1.4.3 Medical Research
    • 1.4.4 Commercial Production
  • 1.5 Global Peptide CDMO Services Market Size & Forecast
  • 1.6 Global Peptide CDMO Services Market Size and Forecast by Region
    • 1.6.1 Global Peptide CDMO Services Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Peptide CDMO Services Market Size by Region, (2018-2029)
    • 1.6.3 North America Peptide CDMO Services Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Peptide CDMO Services Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Peptide CDMO Services Market Size and Prospect (2018-2029)
    • 1.6.6 South America Peptide CDMO Services Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Peptide CDMO Services Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Incyte
    • 2.1.1 Incyte Details
    • 2.1.2 Incyte Major Business
    • 2.1.3 Incyte Peptide CDMO Services Product and Solutions
    • 2.1.4 Incyte Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Incyte Recent Developments and Future Plans
  • 2.2 Gliead
    • 2.2.1 Gliead Details
    • 2.2.2 Gliead Major Business
    • 2.2.3 Gliead Peptide CDMO Services Product and Solutions
    • 2.2.4 Gliead Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Gliead Recent Developments and Future Plans
  • 2.3 Boehringer Ingelheim
    • 2.3.1 Boehringer Ingelheim Details
    • 2.3.2 Boehringer Ingelheim Major Business
    • 2.3.3 Boehringer Ingelheim Peptide CDMO Services Product and Solutions
    • 2.3.4 Boehringer Ingelheim Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Boehringer Ingelheim Recent Developments and Future Plans
  • 2.4 Vertex
    • 2.4.1 Vertex Details
    • 2.4.2 Vertex Major Business
    • 2.4.3 Vertex Peptide CDMO Services Product and Solutions
    • 2.4.4 Vertex Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Vertex Recent Developments and Future Plans
  • 2.5 Mirati Therapeutics
    • 2.5.1 Mirati Therapeutics Details
    • 2.5.2 Mirati Therapeutics Major Business
    • 2.5.3 Mirati Therapeutics Peptide CDMO Services Product and Solutions
    • 2.5.4 Mirati Therapeutics Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Mirati Therapeutics Recent Developments and Future Plans
  • 2.6 AMPAC
    • 2.6.1 AMPAC Details
    • 2.6.2 AMPAC Major Business
    • 2.6.3 AMPAC Peptide CDMO Services Product and Solutions
    • 2.6.4 AMPAC Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 AMPAC Recent Developments and Future Plans
  • 2.7 Pfizer
    • 2.7.1 Pfizer Details
    • 2.7.2 Pfizer Major Business
    • 2.7.3 Pfizer Peptide CDMO Services Product and Solutions
    • 2.7.4 Pfizer Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Pfizer Recent Developments and Future Plans
  • 2.8 Polypeptide
    • 2.8.1 Polypeptide Details
    • 2.8.2 Polypeptide Major Business
    • 2.8.3 Polypeptide Peptide CDMO Services Product and Solutions
    • 2.8.4 Polypeptide Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Polypeptide Recent Developments and Future Plans
  • 2.9 Bachem
    • 2.9.1 Bachem Details
    • 2.9.2 Bachem Major Business
    • 2.9.3 Bachem Peptide CDMO Services Product and Solutions
    • 2.9.4 Bachem Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Bachem Recent Developments and Future Plans
  • 2.10 Merck
    • 2.10.1 Merck Details
    • 2.10.2 Merck Major Business
    • 2.10.3 Merck Peptide CDMO Services Product and Solutions
    • 2.10.4 Merck Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Merck Recent Developments and Future Plans
  • 2.11 Asymchem
    • 2.11.1 Asymchem Details
    • 2.11.2 Asymchem Major Business
    • 2.11.3 Asymchem Peptide CDMO Services Product and Solutions
    • 2.11.4 Asymchem Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Asymchem Recent Developments and Future Plans
  • 2.12 Zhejiang Jiuzhou Pharmaceutical
    • 2.12.1 Zhejiang Jiuzhou Pharmaceutical Details
    • 2.12.2 Zhejiang Jiuzhou Pharmaceutical Major Business
    • 2.12.3 Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Product and Solutions
    • 2.12.4 Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Developments and Future Plans
  • 2.13 Sinopep
    • 2.13.1 Sinopep Details
    • 2.13.2 Sinopep Major Business
    • 2.13.3 Sinopep Peptide CDMO Services Product and Solutions
    • 2.13.4 Sinopep Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Sinopep Recent Developments and Future Plans
  • 2.14 Frontier Biotechnologies
    • 2.14.1 Frontier Biotechnologies Details
    • 2.14.2 Frontier Biotechnologies Major Business
    • 2.14.3 Frontier Biotechnologies Peptide CDMO Services Product and Solutions
    • 2.14.4 Frontier Biotechnologies Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Frontier Biotechnologies Recent Developments and Future Plans
  • 2.15 JYMed
    • 2.15.1 JYMed Details
    • 2.15.2 JYMed Major Business
    • 2.15.3 JYMed Peptide CDMO Services Product and Solutions
    • 2.15.4 JYMed Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 JYMed Recent Developments and Future Plans
  • 2.16 Chengdu Shengnuo Biotechnology
    • 2.16.1 Chengdu Shengnuo Biotechnology Details
    • 2.16.2 Chengdu Shengnuo Biotechnology Major Business
    • 2.16.3 Chengdu Shengnuo Biotechnology Peptide CDMO Services Product and Solutions
    • 2.16.4 Chengdu Shengnuo Biotechnology Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 Chengdu Shengnuo Biotechnology Recent Developments and Future Plans
  • 2.17 Shanghai Soho-Yiming Pharmaceuticals
    • 2.17.1 Shanghai Soho-Yiming Pharmaceuticals Details
    • 2.17.2 Shanghai Soho-Yiming Pharmaceuticals Major Business
    • 2.17.3 Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Product and Solutions
    • 2.17.4 Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Developments and Future Plans
  • 2.18 Chinese Peptide Company
    • 2.18.1 Chinese Peptide Company Details
    • 2.18.2 Chinese Peptide Company Major Business
    • 2.18.3 Chinese Peptide Company Peptide CDMO Services Product and Solutions
    • 2.18.4 Chinese Peptide Company Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.18.5 Chinese Peptide Company Recent Developments and Future Plans
  • 2.19 Ambio Pharmaceuticals
    • 2.19.1 Ambio Pharmaceuticals Details
    • 2.19.2 Ambio Pharmaceuticals Major Business
    • 2.19.3 Ambio Pharmaceuticals Peptide CDMO Services Product and Solutions
    • 2.19.4 Ambio Pharmaceuticals Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.19.5 Ambio Pharmaceuticals Recent Developments and Future Plans
  • 2.20 Zhejiang Peptites Biotech
    • 2.20.1 Zhejiang Peptites Biotech Details
    • 2.20.2 Zhejiang Peptites Biotech Major Business
    • 2.20.3 Zhejiang Peptites Biotech Peptide CDMO Services Product and Solutions
    • 2.20.4 Zhejiang Peptites Biotech Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.20.5 Zhejiang Peptites Biotech Recent Developments and Future Plans
  • 2.21 STA Pharmaceutical
    • 2.21.1 STA Pharmaceutical Details
    • 2.21.2 STA Pharmaceutical Major Business
    • 2.21.3 STA Pharmaceutical Peptide CDMO Services Product and Solutions
    • 2.21.4 STA Pharmaceutical Peptide CDMO Services Revenue, Gross Margin and Market Share (2018-2023)
    • 2.21.5 STA Pharmaceutical Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Peptide CDMO Services Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Peptide CDMO Services by Company Revenue
    • 3.2.2 Top 3 Peptide CDMO Services Players Market Share in 2022
    • 3.2.3 Top 6 Peptide CDMO Services Players Market Share in 2022
  • 3.3 Peptide CDMO Services Market: Overall Company Footprint Analysis
    • 3.3.1 Peptide CDMO Services Market: Region Footprint
    • 3.3.2 Peptide CDMO Services Market: Company Product Type Footprint
    • 3.3.3 Peptide CDMO Services Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Peptide CDMO Services Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Peptide CDMO Services Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Peptide CDMO Services Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Peptide CDMO Services Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Peptide CDMO Services Consumption Value by Type (2018-2029)
  • 6.2 North America Peptide CDMO Services Consumption Value by Application (2018-2029)
  • 6.3 North America Peptide CDMO Services Market Size by Country
    • 6.3.1 North America Peptide CDMO Services Consumption Value by Country (2018-2029)
    • 6.3.2 United States Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Peptide CDMO Services Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Peptide CDMO Services Consumption Value by Type (2018-2029)
  • 7.2 Europe Peptide CDMO Services Consumption Value by Application (2018-2029)
  • 7.3 Europe Peptide CDMO Services Market Size by Country
    • 7.3.1 Europe Peptide CDMO Services Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 7.3.3 France Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Peptide CDMO Services Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Peptide CDMO Services Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Peptide CDMO Services Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Peptide CDMO Services Market Size by Region
    • 8.3.1 Asia-Pacific Peptide CDMO Services Consumption Value by Region (2018-2029)
    • 8.3.2 China Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 8.3.5 India Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Peptide CDMO Services Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Peptide CDMO Services Consumption Value by Type (2018-2029)
  • 9.2 South America Peptide CDMO Services Consumption Value by Application (2018-2029)
  • 9.3 South America Peptide CDMO Services Market Size by Country
    • 9.3.1 South America Peptide CDMO Services Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Peptide CDMO Services Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Peptide CDMO Services Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Peptide CDMO Services Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Peptide CDMO Services Market Size by Country
    • 10.3.1 Middle East & Africa Peptide CDMO Services Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Peptide CDMO Services Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Peptide CDMO Services Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Peptide CDMO Services Market Drivers
  • 11.2 Peptide CDMO Services Market Restraints
  • 11.3 Peptide CDMO Services Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Peptide CDMO Services Industry Chain
  • 12.2 Peptide CDMO Services Upstream Analysis
  • 12.3 Peptide CDMO Services Midstream Analysis
  • 12.4 Peptide CDMO Services Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Peptide CDMO Services. Industry analysis & Market Report on Peptide CDMO Services is a syndicated market report, published as Global Peptide CDMO Services Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Peptide CDMO Services market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,724.84
    4,087.26
    5,449.68
    3,205.08
    4,807.62
    6,410.16
    545,907.60
    818,861.40
    1,091,815.20
    289,362.00
    434,043.00
    578,724.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report